MANY studies in animals have examined biochemical, immune and histological changes during arthritis; however, the study of the effects of arthritis on mobility has been largely neglected. Interleukin-1, administered by the intraarticular route into hamster knee joints, resulted in inhibition of spontaneous wheel running activity; however, the effect was transient, lasting only through the evening following IL-1 administration. A further injection of IL-1 2 days later showed still greater inhibition of running. The effect again did not extend beyond the first evening after injection. IL-Ix and IL-I showed equivalent effects on mobility, and no evidence was seen for cooperative interaction between them. A 50% inhibition of running occurred at a dose of approximately 10 ng/knee of IL-10t. The effect appeared not to be systemic since intraperitoneal injection required microgram amounts of IL-1 for an equivalent inhibition. At the time mobility had been restored to normal, histological examination showed the continued presence of inflammatory cells, soft tissue swelling and cartilage proteoglycan loss. These results suggest a lack of correlation between inhibition of mobility and histopathological changes in cartilage and soft tissue.
Introduction
Interleukin-1 (IL-1) has been suggested as an important mediator of arthritic disease. It has been shown in vitro to accelerate cartilage proteoglycan lOSS 1'2 and to inhibit proteoglycan synthesis.
3,4 IL-1 is known to be an inducer of other cytokines such as IL-65 and the colony stimulating factors (CSFs), and induces adhesion molecules on endothelial cells and chemotactic cytokines such as IL-8. IL-1 can augment the immune response, 9 ,1 contribute to the formation of granulation tissue 11'12 and play a role in nonspecific immunity. 13 All these events are part of the inflammatory process.
IL-1 has been shown to produce inflammation and cartilage proteoglycan loss when injected intraarticularly in the rabbit, [14] [15] [16] mouse 17 and rat. 8 Moreover, IL-1 has been shown to have direct involvement in a murine 19 and in a rat model 2 of arthritis. Previously, it has been shown that systemic administration of IL-1 can lead to decreased locomotor activity in the rat, measured as rearing activity and movement from one quadrant of the cage to another. 21 The possibility was considered that a local arthritis might also affect locomotor activity.
However, preliminary studies of activity in locomotor cages showed only minor effects of arthritis on movement, perhaps because of the limited range of movement possible in a 30 x 45 cm cage. A running wheel offered the possibility of extended running () 1994 Rapid Communications of Oxford Ltd activity that could be modified by arthritis. However, the normal untrained rat shows highly variable running. In contrast, a hamster without training will travel many kilometres a night on a wheel or disk 22 and therefore seemed a better species in which to explore the effects of arthritis on mobility. Thus, the consequences of an arthritis induced by local intraarticular administration of IL-1 on mobility of the hamster were studied. (40 ng) that was four times the amount used to give inflammation, inhibition of proteoglycan synthesis and, after three injections, frank proteoglycan loss in the mouse. 17 The amount reflected a compromise between the differences in dose scaling based on surface area (3 x) and body weight (5 x) of a 125 g hamster and a 25 g mouse. 25 Results of a typical experiment are shown in Fig. 1 (Fig. 4) '6 and it was speculated that its effects would be primarily local under these circumstances. Thus, some of these conclusions may not be applicable to chronic arthritis where an overlay of systemic disease may change mobility in a fundamental way. Recognizing these qualifications, we still felt that simplicity dictated examination of the consequences of an acute local inflammation on mobility. Groups of six hamsters were allowed to run for 3 nights, and a normal nightly distance computed for each hamster. On day 3, IL-lo was administered intraperitoneally and the nightly distance determined.
Methods
Mobility changes with an IL-1 arthritis It was verified that intraarticular IL-1 induced joint inflammation in the hamster. Histologically, as expected from observations in other species, cell infiltration, soft tissue swelling, and proteoglycan loss were observed. The inflammation after a second IL-1 injection was greater than that after the first injection. A single intraarticular saline injection did not prime the joint to a greater response to a subsequent IL-1 injection (data not shown). It is suspected that the enhanced effect of the second IL-1 injection is due to its adminisration into an already inflamed joint. It has previously been shown that intraarticular IL-1 leads to potentiation of the smoldering arthritis induced with streptococcal cell wall peptidoglycan inducing development of much more extensive pannus, soft tissue swelling and cartilage destruction. '7 Thus, it appears that application of IL-1 to a site already infiltrated by inflammatory cells finds the tissue in a position to respond more readily to IL-1.
The second intraarticular injection of IL-1 into a site is also characterized by a greater suppression of daily running distance than the first injection.
When the amount of IL-1 required to obtain an effect on mobility was measured, it was found that a good dose response was obtained in the range of 10-40 ng of IL-1 per joint. This is consistent with the amount of IL-1 which causes histopathological changes and cartilage depletion in mice. 17 Although this amount is well above the levels of IL-1 that can be measured in biological fluids, the rapid distribution and elimination in rodents of murine IL-I and 28 and human IL-I 29'3 means that much larger amounts will be required by bolus injection to match that generated by continuous local production. Moreover, as described above, it is likely that the amount of IL-1 required to amplify an existing inflammatory lesion is much less than the amount of IL-1 required to elicit a full blown inflammation de nouveau. Thus, although it is considered that the amount of IL-1 utilized in these experiments is superphysiological, the changes produced probably reflect those seen following endogenous production. 
